Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $23688.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 260.66% to $23688.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $67067.0, a 155.27% increase, with the full-year FY2024 number at $26272.0, down 85.19% from a year prior.
  • Depreciation & Amortization (CF) was $23688.0 for Q3 2025 at Inhibikase Therapeutics, down from $24158.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $159204.0 in Q2 2023 to a low of $1681.0 in Q3 2022.
  • A 4-year average of $20837.9 and a median of $6568.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 291.61% in 2023, then crashed 95.87% in 2024.
  • Inhibikase Therapeutics' Depreciation & Amortization (CF) stood at $5042.0 in 2022, then skyrocketed by 30.27% to $6568.0 in 2023, then dropped by 0.02% to $6567.0 in 2024, then surged by 260.71% to $23688.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Depreciation & Amortization (CF) are $23688.0 (Q3 2025), $24158.0 (Q2 2025), and $12654.0 (Q1 2025).